Therapeutic Angiogenesis Using Human VEGF-A165/bFGF Plasmid Injected Percutaneously Into the Ischemic Myocardium of "No-option" Coronary Artery Disease Patients; Double-blind Placebo Controlled Study.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs VEGF-FGF plasmid therapy (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms VIF-CAD
Most Recent Events
- 14 Apr 2011 New trial record
- 01 Mar 2011 Results published in the American Heart Journal.
- 01 Dec 2009 Biomarkers information updated